Daan Gene Co.,Ltd.: 2024 Interim Performance Forecast

Sensex a shareJul 10 12:00 ET · Announcements

Daan Gene Co., Ltd (002030.SZ) is expected to suffer a loss of 0.35 billion to 0.43 billion yuan in the first half of the year.

On July 10th, Gelunhui reported that Daan Gene Co., Ltd. (002030.SZ) is expected to lose between 350 million and 430 million yuan in the first half of the year, with a non-net loss of 130 million to 180 million yuan. (1) During the reporting period, due to a decrease in market demand and adjustment of centralized procurement prices, the company's revenue decreased, and net income attributable to shareholders of the listed company decreased from the same period last year. (2) During the reporting period, due to the fair value changes of the company's other non-current financial assets, the impact on net income attributable to shareholders of the listed company was approximately -250 million yuan, which is part of non-recurring gains and losses.

Gelonghui FinanceJul 10 04:26 ET

Daan Gene Co., Ltd. (002030.SZ): As of June 28th, the total number of shareholders in the company is approximately 1,503,000.

Daan Gene Co., Ltd. (002030.SZ) stated on the investor interaction platform on July 8th that as of June 28, 2024, the total number of shareholders in the company was approximately 1.53 million households.

Gelonghui FinanceJul 8 11:00 ET

daan gene co.,ltd. (002030.SZ): Its subsidiary has obtained the medical instruments registration certificate for hepatitis C virus antibody (HCV) control product.

On June 24, Gelonhui reported that Daan Gene Co., Ltd. (002030.SZ) announced that its subsidiary, Guangzhou Darui Biotechnology Co., Ltd., has recently obtained a medical device registration certificate issued by the National Medical Products Administration of China for the Hepatitis C Virus Antibody (HCV) Reference Material. The certificate number is National Machinery Standard 20243401117. The validity period is from the date of approval to June 17, 2029. The expected use is for the critical value correction of the qualitative test of the Hepatitis C Virus Antibody. Currently, the company's subsidiary, Guangzhou Darui Biotechnology Co., Ltd., is the majority shareholder.

Gelonghui FinanceJun 24 05:52 ET

Daan Gene to Raise Subsidiary's Capital by 40 Million Yuan

Chinese medical laboratory company Daan Gene (SHE:002030) plans to increase the capital of subsidiary Guangzhou Datai Bioengineering Technology by 40 million yuan, the company said in its filing on th

MT NewswiresJun 11 02:22 ET

Daan Gene Co., Ltd. (002030.SZ) intends to increase its investment in Datai Biotech by 40 million yuan to expand the market for biochemical and immune diagnostic reagents.

Daan Gene Co., Ltd. (002030.SZ) announced to expand its market of biochemical and immunological testing reagents and support its wholly-owned subsidiary...

Zhitong FinanceJun 7 05:57 ET